Pooled analysis (n = 451) by Daud et al. (188): membranous PD-L1 expression (22C3 mAb) in tumor and immune cells was scored 0–5; higher scores were associated with better ORRs, PFS, and OS; with a ≥1% cutoff for PD-L1+, HR: 0.51 for PFS and 0.50 for OS; ORR: 8–12% in PD-L1− patients (durable response), 22–53% in PD-L1+ patients with a PD-L1 score 2–5. This evidence concerns the gene CD274 and neoplasm.